Results 301 to 310 of about 264,442 (390)

Longitudinal Changes in Diastolic Dysfunction in Heart Failure with Reduced Ejection Fraction: Clinical and Echocardiographic Associations. [PDF]

CJC Open
Al-Mohaissen M, Lee T, Qattea MB.
europepmc   +1 more source

“The Third Man” in Heart Failure　– Heart Failure With Reduce Ejection Fraction Evolved From Heart Failure With Preserved Ejection Fraction –

Circulation Journal, 2015
openaire   +3 more sources

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Beta-Blockers in Heart Failure With Reduced Ejection Fraction: A Systematic Review of Randomized Controlled Trials. [PDF]

Cureus
Elmobark S, Hamad F, Hassan Mutwali LG, Ali Mohamed Zain NQA, Mohamed Z, Mohamed Ahmed TA, Hassan Almzaini OA.   +6 more
europepmc   +1 more source

Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction

, 2019
Jessica A. Regan, Dalane W. Kitzman, Eric Leifer, William E. Kraus, Jerome L. Fleg, Daniel E. Forman, David J. Whellan, Daniel Wojdyla, Kishan S. Parikh, Christopher M. O’Connor, Robert J. Mentz   +10 more
openalex   +2 more sources

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studies. [PDF]

Front Cardiovasc Med
Escobar C, Caravaca-Pérez P, Fernandez Rodriguez JM, Gomez-Otero I, Lozano-Bahamonde A, Pérez-Cabeza AI, Pérez-Silvestre J, Rafols C, Esteban-Fernández A.   +8 more
europepmc   +1 more source

Managing heart failure with reduced ejection fraction merged with myocardial infarction with non-obstructive coronary arteries: a case report [PDF]

So Ikebe, Masahiro Yamamoto, Masanobu Ishii, Eiichiro Yamamoto, Kenichi Tsujita   +4 more
openalex   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

Angiotensin receptor-neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure. [PDF]

ESC Heart Fail
Jung MH, Cho DH, Choi J, Kim MN, Lee CJ, Son JW, Kim Y, Youn JC, Yoo BS.   +8 more
europepmc   +1 more source